Tài liệu Báo cáo y học: "Two-year Outcome of Turkish Patients Treated with Zotarolimus Versus Paclitaxel Elut

In prospective randomized controlled trials, drugeluting stents (DESs) have significantly reduced the rates of restenosis and target lesion revascularization (TLR) over those achieved with bare metal stents (BMSs) in patients with symptomatic coronary artery disease of simple to moderate complexity (1-3) . The use of the Zotarolimus-eluting stent (ZES; Medtronic Vascular, Santa Rosa, CA) for treating single de novo lesions in patients with symptomatic coronary arteryongoing ENDEAVOR clinical trials program. Also the safety and efficacy of Paclitaxel-eluting stent (PES; Taxus, Boston Scientific Corp., Natick, Massachusetts) has been examined in the Taxus I-V studies (5-9). However, the late clinical outcome of ZES and PES in unselected patients treated in daily practice remains controversial.